Business Context and Reporting Period
This Form 8-K Current Report was filed by ImmunityBio, Inc. on August 31, 2023. The filing addresses an update regarding litigation involving Sorrento Therapeutics, Inc. ("Sorrento") and ImmunityBio's wholly-owned subsidiary, NantCell, Inc. ("NantCell").
Key Financial Metrics
This filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on legal proceedings and settlement terms.
Material Changes and Litigation Update
- Settlement Approval: On August 14, 2023, the U.S. Bankruptcy Court for the Southern District of Texas approved a settlement regarding Sorrento's litigation claims against NantCell.
- Non-Payment Status: As of August 31, 2023, Sorrento had not paid judgments held by NantCell and the joint venture Immunotherapy NANTibody LLC ("NANTibody").
- Next Steps: NantCell and NANTibody intend to deliver a certification confirming Sorrento's failure to pay by September 6, 2023.
- Consequences of Non-Payment: If the certification is delivered, the following will become effective immediately:
- A mutual release of claims, releasing the aforementioned judgments and litigation claims (including derivative litigation in the Superior Court of Los Angeles).
- Sorrento will relinquish its interests in NANTibody.
- Sorrento will forfeit rights to payments from NantCell under its antibody exclusive license agreement, including royalties associated with the Phase 2 clinical trial of PD-L1 t-haNK.
Guidance, Risks, and Contingencies
The filing contains forward-looking statements regarding litigation outcomes and business operations. Management highlighted several risks and uncertainties, including:
- Ongoing litigation and court process uncertainties.
- Regulatory review processes and the ability to address FDA complete response letters.
- Ability to secure partnering relationships for commercialization.
- Continuation of preclinical and clinical development programs.
- Ability to obtain additional financing to fund operations.
- Manufacturing scaling and patent protection enforcement.
Investor Verification Checklist
- Verify whether Sorrento Therapeutics, Inc. has paid the outstanding judgments by the September 6, 2023 deadline.
- Confirm the status of the derivative litigation pending in the Superior Court of Los Angeles following the potential mutual release.
- Review the impact of Sorrento forfeiting royalty rights on ImmunityBio's projected revenue from the PD-L1 t-haNK therapy.
- Monitor subsequent filings for updates on the company's liquidity and ability to fund operations given the litigation context.